Skip to main content

Table 3 Dose reduction level

From: Neoadjuvant docetaxel, oxaliplatin and S-1 therapy for the patients with large type 3 or type 4 gastric cancer (OGSG1902): protocol of a multi-center, phase II study

 

Docetaxel

Oxaliplatin

S-1

Level 0

40 mg/m2

100 mg/m2

120 mg/body

100 mg/body

80 mg/body

Level − 1

35 mg/m2

85 mg/m2

100 mg/body

80 mg/body

65 mg/body

Level − 2

30 mg/m2

70 mg/m2

80 mg/body

65 mg/body

50 mg/body

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us